Visão geral da empresa
A biopharmaceutical company operating within the United States and internationally, Innoviva, Inc. generates revenue through a robust royalty portfolio anchored by combination medicines such as RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which provide once-daily treatment options for respiratory conditions. The enterprise functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, positioning it to leverage high-growth therapeutic areas and intellectual property assets rather than traditional product sales models. As of the latest data, the company commands a market capitalization of $1.76B, supported by annual revenues of $411.33M and a workforce comprising 159 employees. These financial figures indicate that Innoviva has achieved a significant scale within the biotechnology landscape, where a market cap of $1.76B suggests substantial market recognition despite the relatively modest headcount, reflecting the high value placed on its proprietary royalty streams and successful licensing agreements.
Saúde financeira
The company reported a trailing twelve-month revenue of $411.33M and a corresponding net income of $271.16M, while generating an EBITDA of $194.99M. The substantial gap between the reported revenue and the net income reveals a highly efficient cost structure where operating expenses and taxes consume less than a third of total sales, resulting in an exceptional profit margin of 65.9%. The firm maintains a free cash flow of $122.07M, which signifies strong financial flexibility to fund R&D initiatives, pursue strategic acquisitions, or return capital to stakeholders without immediate reliance on external financing. Analysis of the profitability metrics shows a gross margin of 74.9%, indicating minimal cost of goods sold typical of royalty-based business models, alongside an operating margin of 34.7% that reflects effective management of overhead and administrative costs. On the balance sheet, Innoviva holds $566.67M in cash against $331.24M in debt, supported by a conservative debt-to-equity ratio of 28.24, which suggests a low-leverage profile that mitigates financial risk during economic downturns. Furthermore, a current ratio of 14.64 demonstrates an abundant liquidity position, providing a massive buffer to cover short-term obligations well over fourteen times current liabilities. Finally, the return on equity stands at 29.1% and the return on assets is 7.2%, metrics that reveal highly effective management in generating profits from shareholder capital and utilizing the total asset base to drive value.
Avaliação de valorização
In terms of valuation multiples, the stock trades at a P/E ratio of 7.16 on a trailing twelve-month basis and a forward P/E of 10.69. The difference between these two figures implies that the market anticipates a significant increase in earnings growth in the coming year, as the forward multiple is notably higher than the trailing multiple, suggesting investors expect the current low P/E to expand. The price-to-book ratio is recorded at 1.50, indicating that the market values the company at fifty percent above its net asset book value, which may reflect the premium assigned to its intangible assets and royalty portfolio. Alternative valuation metrics include a price-to-sales ratio of 4.29 and an EV/EBITDA of 7.76, figures that suggest the market is willing to pay a moderate premium for sales relative to the industry average while valuing earnings before interest, taxes, depreciation, and amortization at a reasonable multiple. Regarding trading ranges, the 52-week high is $25.15 and the 52-week low is $16.52, meaning the current price sits in a position that requires calculation to determine its exact percentage distance from these bounds to assess potential volatility or mean reversion. The beta value is 0.40, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting it may act as a defensive holding that moves less than half as much as the market index during periods of turbulence.
Growth & Income
Innoviva, Inc. has demonstrated robust expansion with a revenue growth rate of 24.8% year over year and an earnings growth rate of 590.4% year over year. The fact that earnings are growing at a rate vastly superior to revenue, specifically 590.4% compared to 24.8%, implies that the company is successfully scaling its royalty portfolio and improving its operational leverage without a proportional increase in costs. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating that management chooses to reinvest all earnings back into the business to accelerate growth rather than distributing cash to shareholders. This strategy aligns with the growth profile of a biotechnology firm that prioritizes expanding its intellectual property assets and market penetration over immediate income generation for investors.